Adult T-cell leukemia future or investigational therapies
|
Adult T-cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adult T-cell leukemia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Adult T-cell leukemia future or investigational therapies |
|
FDA on Adult T-cell leukemia future or investigational therapies |
|
CDC on Adult T-cell leukemia future or investigational therapies |
|
Adult T-cell leukemia future or investigational therapies in the news |
|
Blogs on Adult T-cell leukemia future or investigational therapies |
|
Risk calculators and risk factors for Adult T-cell leukemia future or investigational therapies |
Molecular targeting therapy like targeting therapy against NOTCH1/FBXW7 mutations, JAK-STAT signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia.[1][2]
- ↑ Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J (November 2014). "JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model". Blood. 124 (20): 3092–100. doi:10.1182/blood-2014-04-566687. PMID 25193870.
- ↑ Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG (April 2012). "Targeting nonclassical oncogenes for therapy in T-ALL". Cancer Cell. 21 (4): 459–72. doi:10.1016/j.ccr.2012.02.029. PMID 22516257.